<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493451</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-207</org_study_id>
    <secondary_id>2017-003700-44</secondary_id>
    <secondary_id>CTR20171387</secondary_id>
    <nct_id>NCT03493451</nct_id>
  </id_info>
  <brief_title>Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms</brief_title>
  <official_title>A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to&#xD;
      evaluate the safety and efficacy of BGB-A317 in participants with relapsed or refractory&#xD;
      mature T- and natural killer (NK)-cell neoplasms. There will be two cohorts of participants:&#xD;
&#xD;
        -  Cohort 1: Participants with relapsed or refractory extranodal NK/T cell lymphoma (nasal&#xD;
           or non-nasal type)&#xD;
&#xD;
        -  Cohort 2: other mature T-cell neoplasms (limited to the following histologies:&#xD;
           peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell lymphoma,&#xD;
           or anaplastic large-cell lymphoma)&#xD;
&#xD;
        -  Cohort 3: cutaneous T-cell lymphoma (limited to mycosis fungoides and SÃ¨zary syndrome)&#xD;
&#xD;
      Up to 70 participants will be enrolled into cohort 1, up to 50 participants into cohort 2,&#xD;
      and up to 10 participants into cohort 3 for a total sample size of up to 130 participants.&#xD;
&#xD;
      The primary efficacy endpoint is overall response rate (ORR) determined by investigator&#xD;
      assessment. Disease response for the primary endpoint for cohorts 1 and 2 will be assessed&#xD;
      per the Lugano criteria with LYRIC modification for immunomodulatory therapy Disease response&#xD;
      for the primary endpoint for cohort 3 will be assessed per the International Society for&#xD;
      Cutaneous Lymphoma (ISCL)/European Organization for Research and Treatment of Cancer (EORTC)&#xD;
      guidelines for immunomodulatory therapy BGB-A317 will be administered intravenously as a 200&#xD;
      mg infusion every 3 weeks (Each cycle consists of 21 days). Study procedures will occur over&#xD;
      a Screening phase (up to 35 days); Treatment phase (until disease progression, intolerable&#xD;
      toxicity, or withdrawal of informed consent, whichever occurs first); Safety Follow-up phase&#xD;
      (up to 90 days following last study treatment for all adverse events (AEs) and serious&#xD;
      adverse events (SAEs)); Survival follow-up phase (duration varying by participant).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2018</start_date>
  <completion_date type="Actual">May 11, 2021</completion_date>
  <primary_completion_date type="Actual">May 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) for Cohort 1 and 2</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) per the Lugano criteria with LYRIC modification for immunomodulatory drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) for Cohort 3</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) measured using the ISCL/EORTC guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) for all cohorts</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DOR is the time from the first determination of an objective response until progression or death, whichever occurs first, for all cohorts. Determined per the Lugano criteria with LYRIC modification for immunomodulatory drugs for cohort 1 and 2, and using the ISCL/EORTC guidelines for cohort 3 as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) for all cohorts</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the time from first study drug administration to the date of disease progression or death, whichever occurs first, for all cohorts. Determined per the Lugano criteria with LYRIC modification for immunomodulatory drugs for cohort 1 and 2, and using the ISCL/EORTC guidelines for cohort 3 as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) ) for cohort 1 and cohort 2</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS is defined as the time from first study drug administration to the date of death due to any reason, for cohorts 1 and 2. Determined per the Lugano criteria with LYRIC modification for immunomodulatory drugs for cohort 1 and 2 as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete response or complete metabolic response for all cohorts.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the proportion of patients who achieve complete response or complete metabolic response as best overall response, for all cohorts. Determined per the Lugano criteria with LYRIC modification for immunomodulatory drugs for cohort 1 and 2, and using the ISCL/EORTC guidelines for cohort 3 as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) as assessed by the investigator</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>TRR is defined as the time from first study drug administration to the time the response criteria (complete response or partial response) are first met, for all cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) for all cohorts</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The EORTC QLQ-C30 is completed by the participant. The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes based on EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) for all cohorts</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The EQ-5D- is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system has two versions, namely the 3L and 5L, both involving five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). In the EQ-5D-5L that will be used, participants may choose from the following five response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Peripheral T Cell Lymphoma</condition>
  <condition>PTCL</condition>
  <condition>Extranodal NK/T-cell Lymphoma</condition>
  <condition>Extranodal NK/T-cell Lymphoma, Nasal Type</condition>
  <condition>Extranodal NK T Cell Lymphoma</condition>
  <condition>Extranodal NK T Cell Lymphoma, Nasal</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-Cell Lymphoma Recurrent</condition>
  <condition>Angioimmunoblastic T-Cell Lymphoma Refractory</condition>
  <condition>Peripheral T-cell Lymphoma NOS</condition>
  <condition>Peripheral T-Cell Lymphoma, Not Otherwise Specified</condition>
  <condition>Peripheral T-Cell Lymphoma Refractory</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma, ALK-Positive</condition>
  <condition>Anaplastic Large Cell Lymphoma, ALK-negative</condition>
  <condition>ALK-negative Anaplastic Large Cell Lymphoma</condition>
  <condition>ALK-Positive Anaplastic Large Cell Lymphoma</condition>
  <condition>Cutaneous T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>NK/T cell lymphoma and with other mature T-cell neoplasms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this cohort, participants will be treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle.BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.&#xD;
Cohort 1: Participants with relapsed or refractory extranodal NK/T cell lymphoma (nasal or non-nasal type)&#xD;
Cohort 2: other mature T-cell neoplasms (limited to the following histologies: peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell lymphoma, or anaplastic large-cell lymphoma)&#xD;
Cohort 3: cutaneous T-cell lymphoma (limited to mycosis fungoides and SÃ¨zary syndrome)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>200 mg IV on Day 1 of each 21-day cycle.</description>
    <arm_group_label>NK/T cell lymphoma and with other mature T-cell neoplasms</arm_group_label>
    <other_name>BGB-A317</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
          -  Confirmed diagnosis of relapsed or refractory extranodal NK/T-cell lymphoma (nasal or&#xD;
             non-nasal type, peripheral T-cell lymphoma - not otherwise specified,&#xD;
             angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides,&#xD;
             or Sezary syndrome&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Relapsed or refractory to at least 1 prior systemic therapy&#xD;
&#xD;
          -  Measurable disease by CT/magnetic resonance imaging (MRI) for participants in Cohort 1&#xD;
             and 2&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
          -  Life expectancy â¥ 6 months&#xD;
&#xD;
          -  Adequate respiratory function&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Adequate renal and hepatic function&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
          -  Known central nervous system (CNS) involvement by lymphoma&#xD;
&#xD;
          -  Previously received immune checkpoint therapy&#xD;
&#xD;
          -  Prior malignancy within the past 3 years, except for curatively treated basal or&#xD;
             squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix&#xD;
             or breast, or localized Gleason score 6 or lower prostate cancer&#xD;
&#xD;
          -  Active autoimmune disease or history of autoimmune diseases that may relapse with some&#xD;
             exceptions&#xD;
&#xD;
          -  Severe or debilitating pulmonary disease&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Active fungal, bacterial, and/or viral infection requiring systemic therapy&#xD;
&#xD;
          -  Known infection with HIV or active viral hepatitis B or C infection&#xD;
&#xD;
          -  Major surgery within 4 weeks of the first dose of study drug&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Vaccination with a live vaccine within 35 days prior to the first dose of study drug&#xD;
&#xD;
          -  Hypersensitivity to tislelizumab&#xD;
&#xD;
          -  Concurrent participation in another therapeutic clinical trial&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Paik, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert &amp; Medical College of Wisconsin - Froedtert Hospital - Clinical Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UBC - British Columbia Cancer Agency - The Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>He Nan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>He Nan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The affiliated hospital of Xuzhou medical university</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan university Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut d'hÃ©matologie de Basse Normandie</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-BÃ©nite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsmedizin GÃ¶ttingen</name>
      <address>
        <city>GÃ¶ttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Leipzig AÃ¶R</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>00000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>Emilia</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore, AOU Parma</name>
      <address>
        <city>Parma</city>
        <state>Emilia</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino - IRCCS per l'Oncologia</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXII</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Pisana, Stabilimento di Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria di Terni</name>
      <address>
        <city>Terni</city>
        <state>Umbria</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T/NK-cell</keyword>
  <keyword>NK/T-cell</keyword>
  <keyword>extranodal</keyword>
  <keyword>nasal</keyword>
  <keyword>NK-cell</keyword>
  <keyword>ENKTL</keyword>
  <keyword>peripheral T-cell</keyword>
  <keyword>anaplastic large cell</keyword>
  <keyword>ALCL</keyword>
  <keyword>angioimmunoblastic</keyword>
  <keyword>PTCL-NOS</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

